Divi's Laboratories Ltd. Share Price

Technical Evaluation: Divis Laboratories (Daily Chart)

The stock

Indian Pharma Gains From US Zero-Tariff Clarity

“Why No-Trade Can Be a Smart Decision” .

Trading is not about finding an opportunity in every market condition. Sometimes price action remains unclear, volatility becomes unpredictable or the risk-to-reward relationship does not justify taking a position. In such situations, staying out can be a disciplined trading decision. A good setup should provide a clear reason for entry, a logical point where the idea becomes invalid and sufficient potential reward for the risk being taken. When these conditions are missing, forcing a trade can increase unnecessary exposure. Experienced traders understand that capital preservation is part of long-term performance. Waiting for better conditions allows traders to remain prepared when a higher-quality opportunity eventually appears. Learning: Not taking a trade is also a decision, especially when the setup does not offer a clear advantage.

Bharat Health Expo 2026: Pharma & Supply Chain

Speaking at the Bharat Health Global Expo 2026 in New Delhi, Union Minister of Commerce and Industry Piyush Goyal called for India to transform its pharmaceutical leadership by moving beyond generic drugs toward research, innovation, and resilient, globally integrated healthcare supply chains. Joined by Minister of State Jitin Prasada and Commerce Secretary Rajesh Agarwal, Mr. Goyal stressed the need to secure domestic supply chains for Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs), while urging Indian companies to invest in overseas markets for localized value addition and last-mile distribution. To accelerate this transition, he advocated for heightened focus on biosimilars, novel molecules, and biotechnology—supported by the Research and Development Innovation Fund—alongside regulatory alignment with developed markets to attract foreign direct investment. Highlighting industrial infrastructure, Mr. Goyal pointed to ongoing bulk drug park developments in Andhra Pradesh, Gujarat, and Himachal Pradesh, as well as plans for 100 plug-and-play industrial parks tailored for the healthcare and pharmaceutical sectors. He also urged a mission-mode strategy to capture the nearly ₹76,352 crore ($8 billion) medical value travel market. Emphasizing trade expansion, the Minister contrasted India's pre-2014 Free Trade Agreements (FTAs)—which covered a combined GDP of ₹954.40 lakh crore ($10 trillion)—with nine recently concluded FTAs unlocking access to ₹5,726.40 lakh crore ($60 trillion) in global GDP. He noted that active negotiations for 8 to 10 additional trade deals aim to provide Indian exporters access to 75% of total global trade.

Divi’s Laboratories (DIVISLAB) has delivered a very strong

“Why Overconfidence Can Be as Dangerous as Fear”

Fear is often discussed as a major problem in trading, but overconfidence can create equally damaging decisions. After a series of successful trades, a trader may begin to believe that the next trade is also likely to succeed. This can lead to larger positions, weaker setups and reduced attention to risk. A professional approach treats every new opportunity independently. Previous profits do not provide additional certainty about the next market movement. The same entry criteria, risk limits and execution rules should continue to apply regardless of recent performance. Overconfidence can also appear after correctly predicting a major market move. Being right once does not mean that every future prediction will be correct. Markets continuously change, and no trader can eliminate uncertainty completely. Maintaining discipline after winning trades is therefore an important part of long-term consistency. Learning: A winning streak should increase your discipline, not your willingness to take unnecessary risk.